David Raben, MD, FASTRO

University of Colorado

Disclosure:
Employment
Radiation Oncology, Univ of Colorado Health: Professor: Employee

Compensation
Astra Zeneca: Advisory Board, Consultant; Genentech: Advisory Board; Merck: Advisory Board, Honoraria; Nanobiotix: Advisory Board, Honoraria; Suvica: Consultant

Biography:
David Raben, M.D. is currently faculty at the University of Colorado where he is a board-certified Professor of Radiation Oncology holding the Marsico Endowed Chair for HNC Research. He received a B.A. in Psychology from Duke University in 1985 and then completed his M.D. at Wake Forest University/Bowman Grey School of Medicine in 1990. After graduation, he did his internship at the University of Hawaii and residency in Radiation Oncology at the Johns Hopkins Hospital from 1991-1994, serving as a chief resident in 1994. He took his initial faculty position at the University of Alabama at Birmingham from 1994-1998 before joing the University of Colorado. Dr. Raben has developed expertise over the past 20 years in translational radiation oncology with a focus on delivery of precision drugs and exploration of molecular biomarkers that will enhance the effects of radiation therapy. He serves on the NRG HNC steering committee and translational committee focusing on NCI approved clinical trials devoted to HNC. Dr. Raben also serves on the SWOG GU Steering committee for prostate and bladder cancer. He currently serves as the Developmental Therapeutics co-Chair at the NRG with responsibilities to initiate and implement Phase I trials with radiation and novel drugs. From a research perspective, his focus has been on heavy smoker HNC patients who have high levels of DNA repair capabilities offering approaches that will inhibit DNA repair while studying which biomarkers might predict response. Additional work has focused on the use of TGFb inhibitors as both radioprotectors and to enhance anti-PDL1 inbibition in head and neck models. Recently accepted for publication was the first radiation trial with an anti-EGFR inhibitor and a PARP inhibitor in locally advanced HNC. Dr Raben was named as an ASCO daily News Associate Editor in 2018. He has authored over 150 publications.

Presentation(s):

LBA10 - PACIFIC: Overall Survival with Durvalumab versus Placebo after Chemoradiotherapy in Stage III NSCLC
Tuesday, October 23
8:05 AM – 8:15 AM
Meet the Expert - Head and Neck
Tuesday, October 23
1:30 PM – 1:50 PM
Riding the Waves of Immunotherapy and Radiation - How to Ride the Right One
Wednesday, October 24
2:38 PM – 2:55 PM

Send Email for David Raben

Subject

Body

<h1>  shared a speaker with you!</h1><div><b>Name:</b> David Raben</div><div><b>Organization:</b> University of Colorado</div><div><b>Position:</b> Not Available</div><div><b>Bio:</b> David Raben, M.D. is currently faculty at the University of Colorado where he is a board-certified Professor of Radiation Oncology holding the Marsico Endowed Chair for HNC Research. He received a B.A. in Psychology from Duke University in 1985 and then completed his M.D. at Wake Forest University/Bowman Grey School of Medicine in 1990. After graduation, he did his internship at the University of Hawaii and residency in Radiation Oncology at the Johns Hopkins Hospital from 1991-1994, serving as a chief resident in 1994. He took his initial faculty position at the University of Alabama at Birmingham from 1994-1998 before joing the University of Colorado. Dr. Raben has developed expertise over the past 20 years in translational radiation oncology with a focus on delivery of precision drugs and exploration of molecular biomarkers that will enhance the effects of radiation therapy. He serves on the NRG HNC steering committee and translational committee focusing on NCI approved clinical trials devoted to HNC. Dr. Raben also serves on the SWOG GU Steering committee for prostate and bladder cancer. He currently serves as the Developmental Therapeutics co-Chair at the NRG with responsibilities to initiate and implement Phase I trials with radiation and novel drugs.  From a research perspective, his focus has been on heavy smoker HNC patients who have high levels of DNA repair capabilities offering approaches that will inhibit DNA repair while studying which biomarkers might predict response. Additional work has focused on the use of TGFb inhibitors as both radioprotectors and to enhance anti-PDL1 inbibition in head and neck models. Recently accepted for publication was the first radiation trial with an anti-EGFR inhibitor and a PARP inhibitor in locally advanced HNC.  Dr Raben was named as an ASCO daily News Associate Editor in 2018. He has authored over 150 publications. 
</div>